These mutations increase EGFR amplification and interleukin 6 (IL-6) levels, inducing angiogenesis and tumor necrosis [48], and decrease glycogen accumulation, limiting glucose oxidation, nucleic acid and de novo fatty acid synthesis, and promoting tumor cell apoptosis [49]. The gene discussed is EGFR; the disease is neoplasm.